NCT02531854View on ClinicalTrials.gov

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2018

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

ADXS11-001

ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.

DRUG

Pemetrexed

Chemotherapy

Sponsors

Lead Sponsor

Advaxis, Inc.
All Listed Sponsors
lead

Advaxis, Inc.

INDUSTRY

NCT02531854 - A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | Biotech Hunter | Biotech Hunter